> Presentation of the Neurolead platform

Theranexus' strategy in the field of rare central nervous system diseases is based on its NeuroLead platform, in collaboration with the Collège de France and the French Atomic Energy Commission and Alternatives Energy (CEA).

This unique platform, equipped with the latest innovations in neuroscience, capitalizes on Theranexus' expertise in neuron-glia interactions and its know-how in the production of human pathological cell models to identify new targets and develop innovative drug candidates for rare neurological diseases.